WCLC 2022 Archives - Medical Conferences

Home > Oncology > WCLC 2022

Read the full Report (pdf)

IASLC World Conference on Lung Cancer
06–09 August 2022
Vienna, Austria

Table of Contents

Colophon

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

WCLC 2022

Type

News article

23 August 2022 11:02

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

Presented By

Dr Nasser Altorki, Weill Cornell Medicine, NY, USA

Trial

Phase 3, CALGB 140503

Conference

WCLC 2022

Type

News article

23 August 2022 10:57

Online First

WCLC 2022 Congress Round-Up

Sugemalimab offers PFS benefits for unresectable NSCLC

Presented By

Prof. Yi-Long Wu, Guangdong Provincial People’s Hospital, China

Trial

Phase 3, GEMSTONE-301

Conference

WCLC 2022

Type

News article

23 August 2022 11:10

First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1, CodeBreaK 100/101

Conference

WCLC 2022

Type

News article

23 August 2022 11:08

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

WCLC 2022

Type

News article

23 August 2022 11:02

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

Presented By

Dr Nasser Altorki, Weill Cornell Medicine, NY, USA

Trial

Phase 3, CALGB 140503

Conference

WCLC 2022

Type

News article

23 August 2022 10:57

NADIM: Risk of progression identified through RNA sequencing

Presented By

Ms Marta Casarrubios, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

WCLC 2022

Type

News article

23 August 2022 10:55

NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

Presented By

Dr Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM II

Conference

WCLC 2022

Type

News article

23 August 2022 10:52

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented By

Prof. Solange Peters, Lausanne University, Switzerland

Trial

Phase 3, POSEIDON

Conference

WCLC 2022

Type

News article

23 August 2022 10:47

First DLL3-targeted therapy shows promise in SCLC

Presented By

Prof. Hossein Borghaei, Fox Chase Cancer Center, PA, USA

Trial

Phase 1

Conference

WCLC 2022

Type

News article

23 August 2022 10:43

KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, KEYNOTE-604

Conference

WCLC 2022

Type

News article

23 August 2022 10:41

Talazoparib plus temozolomide appears efficacious in ES-SCLC

Presented By

Dr Jonathan Goldman, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 2

Conference

WCLC 2022

Type

News article

23 August 2022 10:37

Pembrolizumab plus lenvatinib performs well in MPM

Presented By

Dr Li-Anne Douma, Netherlands Cancer Institute - Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 2, PEMMELA

Conference

WCLC 2022

Type

News article

23 August 2022 10:34

Early detection strategies in younger patients with lung cancer are urgently needed

Presented By

Dr Alexandra Potter, Massachusetts General Hospital, MA, USA

Conference

WCLC 2022

Type

News article

23 August 2022 10:27

Intensive co-located smoking cessation programme highly effective during lung screening

Presented By

Prof. Rachael Murray, University of Nottingham, UK

Trial

YESS

Conference

WCLC 2022

Type

News article

23 August 2022 10:24

Do we underestimate the effect of air pollution on lung cancer incidence?

Presented By

Dr Renelle Myers, University of British Columbia, Canada

Conference

WCLC 2022

Type

News article

23 August 2022 10:21

Interventions needed to address sexual health in lung cancer

Presented By

Dr Narjust Florez, Dana Farber Cancer Institute, MA, USA

Trial

SHAWL

Conference

WCLC 2022

Type

News article

23 August 2022 10:18

Medical Conferences

WCLC 2022

Featured articles

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

CONTENTS

Online First

WCLC 2022 Congress Round-Up

Sugemalimab offers PFS benefits for unresectable NSCLC

First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

NADIM: Risk of progression identified through RNA sequencing

NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

First DLL3-targeted therapy shows promise in SCLC

KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC

Talazoparib plus temozolomide appears efficacious in ES-SCLC

Pembrolizumab plus lenvatinib performs well in MPM

Early detection strategies in younger patients with lung cancer are urgently needed

Intensive co-located smoking cessation programme highly effective during lung screening

Do we underestimate the effect of air pollution on lung cancer incidence?

Interventions needed to address sexual health in lung cancer